VEGFA and age-related macular degeneration: For example, pegaptanib (a 28-base RNA aptamer targeting VEGF) and bevacizumab (a humanized VEGF monoclonal antibody) significantly alleviate the progression of AMD by inhibiting the activity of VEGF in the retina tissues [8,9].